Skip to content

Income Tax at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$561M+10.2%
Merck & Co. logo
Merck & Co.MRK
$709M-13.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$104M+8.0%
AbbVie logo
AbbVieABBV
$342M-8.1%
Incyte logo
IncyteINCY
$40.27M-47.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$64K+23.1%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.62B+226%

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's income tax?
Arcus Biosciences (RCUS) reported income tax of $0 in Q1 2026.
What is the long-term trend for Arcus Biosciences's income tax?
Over 4 years (2021 to 2025), Arcus Biosciences's income tax has grown at a -100.0% compound annual growth rate (CAGR), from $2M to $0.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.